NurExone Biologic Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	0.7	0.54	2.46	2.21
Cash & Short-Term Investments	0.7	0.54	2.46	2.21
Cash Growth	29.39%	-78.03%	11.25%	-
Other Receivables	0.13	0.1	0.05	0.52
Receivables	0.13	0.1	0.05	0.52
Prepaid Expenses	0.77	0.11	0.12	0.09
Restricted Cash	-	1.2	-	-
Other Current Assets	0.04	0.03	0.05	0.02
Total Current Assets	1.63	1.98	2.69	2.84
Property, Plant & Equipment	0.81	0.19	0.1	-
Total Assets	2.44	2.17	2.79	2.84
Accrued Expenses	0.34	0.55	0.46	0.18
Short-Term Debt	-	1.2	-	1.04
Current Portion of Leases	0	0.02	-	-
Other Current Liabilities	0.06	0.15	0.15	0.41
Total Current Liabilities	0.4	1.91	0.6	1.63
Long-Term Leases	0.03	0	0.02	-
Other Long-Term Liabilities	0.25	0.07	0.08	0.03
Total Liabilities	0.68	1.98	0.7	1.66
Additional Paid-In Capital	17.62	12.16	11.25	3.26
Retained Earnings	-19.1	-14.06	-10.42	-2.25
Comprehensive Income & Other	3.24	2.08	1.26	0.17
Shareholders' Equity	1.76	0.19	2.1	1.18
Total Liabilities & Equity	2.44	2.17	2.79	2.84
Total Debt	0.03	1.22	0.02	1.04
Net Cash (Debt)	0.67	-0.68	2.44	1.17
Net Cash Growth	-	-	108.63%	-
Net Cash Per Share	0.01	-0.02	0.06	0.07
Filing Date Shares Outstanding	78.01	65.81	42.86	34.47
Total Common Shares Outstanding	71.07	48.25	42.86	34.47
Working Capital	1.24	0.07	2.09	1.21
Book Value Per Share	0.02	0.00	0.05	0.03
Tangible Book Value	1.76	0.19	2.1	1.18
Tangible Book Value Per Share	0.02	0.00	0.05	0.03
Machinery	0.48	0.17	0.05	-
Leasehold Improvements	0.35	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.